Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Regenxbio stock
Learn how to easily invest in Regenxbio stock.
Regenxbio Inc is a biotechnology business based in the US. Regenxbio shares (RGNX) are listed on the NASDAQ and all prices are listed in US Dollars. Regenxbio employs 372 staff and has a trailing 12-month revenue of around $484.3 million.
How to buy shares in Regenxbio
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RGNX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Regenxbio stock price (NASDAQ: RGNX)Use our graph to track the performance of RGNX stocks over time.
Regenxbio shares at a glance
|Latest market close||$22.86|
|52-week range||$18.69 - $44.44|
|50-day moving average||$30.96|
|200-day moving average||$28.20|
|Wall St. target price||$51.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$2.11|
Buy Regenxbio shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Regenxbio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Regenxbio price performance over time
|1 week (2022-09-16)||-12.01%|
|1 month (2022-08-25)||-32.51%|
|3 months (2022-06-24)||-13.74%|
|6 months (2022-03-24)||-28.47%|
|1 year (2021-09-24)||-45.98%|
|2 years (2020-09-25)||-17.92%|
|3 years (2019-09-25)||34.86|
|5 years (2017-09-25)||30.95|
Is Regenxbio stock undervalued or overvalued?
Valuing Regenxbio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regenxbio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regenxbio's P/E ratio
Regenxbio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Regenxbio shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regenxbio's PEG ratio
Regenxbio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.26. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regenxbio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regenxbio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $132.9 million.
The EBITDA is a measure of a Regenxbio's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$484.3 million|
|Operating margin TTM||25.23%|
|Gross profit TTM||$237.1 million|
|Return on assets TTM||8.53%|
|Return on equity TTM||15.95%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
Regenxbio share dividends
We're not expecting Regenxbio to pay a dividend over the next 12 months.
Regenxbio share price volatility
Over the last 12 months, Regenxbio's shares have ranged in value from as little as $18.69 up to $44.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regenxbio's is 1.0927. This would suggest that Regenxbio's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
REGENXBIO Inc. , a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies.
Regenxbio in the news
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
Frequently asked questionsWhat percentage of Regenxbio is owned by insiders or institutions?
Currently 12.097% of Regenxbio shares are held by insiders and 91.514% by institutions. How many people work for Regenxbio?
Latest data suggests 372 work at Regenxbio. When does the fiscal year end for Regenxbio?
Regenxbio's fiscal year ends in December. Where is Regenxbio based?
Regenxbio's address is: 9804 Medical Center Drive, Rockville, MD, United States, 20850 What is Regenxbio's ISIN number?
Regenxbio's international securities identification number is: US75901B1070 What is Regenxbio's CUSIP number?
Regenxbio's Committee on Uniform Securities Identification Procedures number is: 75901B107
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert